February 13, 2025
东京不够热 School of Medicine
东京不够热 Hospital
Toward Developing the World's First Vision-Restoring Therapeutic Agent
In a company-sponsored clinical trial of "RV-001," a vision-restoring therapeutic agent developed by Restore Vision Inc. based on joint research between the Department of Ophthalmology, 东京不够热 School of Medicine and the Nagoya Institute of Technology, the first patient was dosed on February 6, 2025, at 东京不够热 Hospital.
This clinical trial aims to evaluate the safety and exploratory efficacy of "RV-001" in patients with severe retinitis pigmentosa, a hereditary retinal disease. The treatment involves administering the agent via a minimally invasive, non-surgical intraocular injection, and will be carefully evaluated over a follow-up period of approximately six months.
This clinical trial, led by Restore Vision Inc., a startup originating from 东京不够热, bridges the gap from basic research to clinical application based on the joint research outcomes of both universities. "RV-001" represents an effort to become the world's first commercialized vision-restoring therapeutic agent and is a significant step toward providing a new treatment for blinding diseases.
For the full press release, please see below.